Treat to target approach has gained a lot of popularity due to its proven efficacy in the treatment of Rheumatoid arthritis (RA). However, the effect of this approach has not been studied in PsA patients. John L. O'Dwyer and colleagues conducted a study to estimate whether the TC of inflammation in early PsA is cost-effective as compared to conventional care.

Along with a UK‐based, open‐label, multicenter, randomized controlled trial, cost-effective analyses were initiated. 3‐level EuroQol 5‐domain was used to measure the effectiveness which provided the calculation of quality-adjusted-life-years (QALYs). Incremental cost‐effectiveness ratios (ICERs) were also presented, which described the additional cost per QALY increased over a 48‐week time limit. Sensitivity analyses were also presented evaluating the effect of modifications in the analytical approach and assumptions on the cost‐effectiveness judgments.

The results were evaluated, in which mean cost and QALYs showed higher readings than TC group. Further, these values yielded an ICER of £53948 per QALY. The bootstrapped uncertainty analysis evaluated that the TC has 0.07 probability of being cost-effective at a £20,000 threshold. It has also been analyzed that even with certain controlled costs, an ICER of £24639 can be determined with a greater degree of disease severity.